Payment overview · 2025
General Payments
$374.77
8 reported records · 6 companies
Healthcare provider profile · identity verified
Robert Marcelino Rivera Alburo, MD
Allopathic & Osteopathic Physicians|Family Medicine · IVA, SC · NPI 1699979310
Verified facts
What the public records show
CMS Open Payments records show Robert Marcelino Rivera Alburo, MD received $374.77 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 47.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $178.15 | 47.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $130.46 | 34.8% | 2 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $20.81 | 5.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.27 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.75 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.33 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $358.50 | 7 |
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $178.15 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $130.46 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $55.60 | 1 | 2025 |
Source payment records
|
|||||
| POLARSTEM Normalized: polarstem |
Device | Smith+Nephew, Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| REAL INTELLIGENCE Normalized: real intelligence |
Device | Smith+Nephew, Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 53 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 615 | 159 |
| Omeprazole | Omeprazole | 374 | 102 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 335 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 315 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 303 | 88 |
| Furosemide | Furosemide | 282 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 282 | 73 |
| Gabapentin | Gabapentin | 265 | 71 |
| Lisinopril | Lisinopril | 264 | 75 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 78 |
| Losartan Potassium | Losartan Potassium | 256 | 69 |
| Zolpidem Tartrate | Zolpidem Tartrate | 219 | 34 |
| Metformin Hcl | Metformin Hcl | 188 | 54 |
| Montelukast Sodium | Montelukast Sodium | 170 | 52 |
| Tramadol Hcl | Tramadol Hcl | 169 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 41 |
| Carvedilol | Carvedilol | 165 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 148 | 35 |
| Prednisone | Prednisone | 147 | 101 |
| Clonazepam | Clonazepam | 146 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 34 |
| Methylprednisolone | Methylprednisolone | 144 | 116 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 142 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 142 | 36 |
| Lorazepam | Lorazepam | 118 | 28 |
| Meloxicam | Meloxicam | 111 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 36 |
| Celecoxib | Celecoxib | 106 | 25 |
| Allopurinol | Allopurinol | 105 | 29 |
| Jardiance | Empagliflozin | 105 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 104 | 32 |
| Trazodone Hcl | Trazodone Hcl | 103 | 32 |
| Eliquis | Apixaban | 102 | 29 |
| Simvastatin | Simvastatin | 97 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 24 |
| Glipizide Er | Glipizide | 94 | 28 |
| Alendronate Sodium | Alendronate Sodium | 91 | 25 |
| Baclofen | Baclofen | 90 | 30 |
| Cefuroxime | Cefuroxime Axetil | 86 | 78 |
| Mirtazapine | Mirtazapine | 86 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 77 | 19 |
| Metformin Hcl Er | Metformin Hcl | 77 | 21 |
| Famotidine | Famotidine | 75 | 19 |
| Finasteride | Finasteride | 75 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 18 |
| Potassium Chloride | Potassium Chloride | 75 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 74 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 16 |
| Spironolactone | Spironolactone | 72 | 23 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 71 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 70 | 12 |
| Doxepin Hcl | Doxepin Hcl | 69 | 14 |
| Temazepam | Temazepam | 69 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 12 |
| Sertraline Hcl | Sertraline Hcl | 67 | 16 |
| Bupropion Xl | Bupropion Hcl | 65 | 15 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 64 | 52 |
| Glipizide | Glipizide | 64 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 53 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 14 |
| Levofloxacin | Levofloxacin | 54 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 16 |
| Farxiga | Dapagliflozin Propanediol | 53 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 22 |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 50 | 11 |
| Rybelsus | Semaglutide | 49 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 48 | 38 |
| Diazepam | Diazepam | 48 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 13 |
| Valsartan | Valsartan | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | 11 |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Trulicity | Dulaglutide | 38 | 14 |
| Atenolol | Atenolol | 37 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | 12 |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Ozempic | Semaglutide | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Azithromycin | Azithromycin | 34 | 30 |
| Sildenafil Citrate | Sildenafil Citrate | 34 | 11 |
| Topiramate | Topiramate | 34 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 33 | 13 |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | suppressed |
| Fluconazole | Fluconazole | 32 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | suppressed |
| Klor-Con M20 | Potassium Chloride | 31 | 14 |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Colchicine | Colchicine | 29 | 17 |
| Risperidone | Risperidone | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 17 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 19 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $374.77 · 8 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, MOUNJARO, Ozempic, POLARSTEM, REAL INTELLIGENCE, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error